Query psy14246
Match_columns 286
No_of_seqs 202 out of 1763
Neff 7.4
Searched_HMMs 46136
Date Fri Aug 16 23:06:10 2013
Command hhsearch -i /work/01045/syshi/Psyhhblits/psy14246.a3m -d /work/01045/syshi/HHdatabase/Cdd.hhm -o /work/01045/syshi/hhsearch_cdd/14246hhsearch_cdd -cpu 12 -v 0
No Hit Prob E-value P-value Score SS Cols Query HMM Template HMM
1 cd01327 KAZAL_PSTI Kazal-type 99.6 2.7E-15 5.9E-20 99.5 3.9 43 232-274 3-45 (45)
2 smart00280 KAZAL Kazal type se 99.6 3.6E-15 7.7E-20 99.5 4.2 45 230-274 2-46 (46)
3 PF00050 Kazal_1: Kazal-type s 99.4 3.1E-13 6.6E-18 90.9 2.9 41 234-274 8-48 (48)
4 smart00280 KAZAL Kazal type se 99.3 6.1E-13 1.3E-17 88.6 3.0 43 77-119 2-46 (46)
5 PF07648 Kazal_2: Kazal-type s 99.3 5.2E-13 1.1E-17 86.9 2.4 41 234-274 1-42 (42)
6 cd01327 KAZAL_PSTI Kazal-type 99.3 7.9E-13 1.7E-17 87.6 3.1 41 79-119 3-45 (45)
7 cd00104 KAZAL_FS Kazal type se 99.3 1.7E-12 3.6E-17 84.3 3.8 41 234-274 1-41 (41)
8 cd01328 FSL_SPARC Follistatin- 99.1 6E-11 1.3E-15 88.9 3.7 49 228-276 23-85 (86)
9 PF07648 Kazal_2: Kazal-type s 99.1 3E-11 6.4E-16 78.6 1.2 39 81-119 1-42 (42)
10 cd00104 KAZAL_FS Kazal type se 99.1 7.8E-11 1.7E-15 76.3 2.8 39 81-119 1-41 (41)
11 PF00050 Kazal_1: Kazal-type s 99.0 8.3E-11 1.8E-15 79.0 1.8 39 81-119 8-48 (48)
12 cd01328 FSL_SPARC Follistatin- 98.9 6.1E-10 1.3E-14 83.5 2.8 47 4-51 13-61 (86)
13 KOG4578|consensus 98.4 1.7E-07 3.6E-12 85.4 2.0 79 14-104 31-117 (421)
14 KOG4578|consensus 98.2 3.1E-07 6.8E-12 83.7 0.8 79 75-156 32-115 (421)
15 cd01330 KAZAL_SLC21 The kazal- 97.4 6.9E-05 1.5E-09 51.4 1.5 28 21-51 11-38 (54)
16 cd01330 KAZAL_SLC21 The kazal- 97.4 7.9E-05 1.7E-09 51.1 1.6 27 79-105 9-36 (54)
17 KOG3555|consensus 97.2 0.00015 3.3E-09 66.8 2.3 50 232-281 140-190 (434)
18 KOG3555|consensus 96.3 0.002 4.3E-08 59.7 1.7 43 79-121 140-185 (434)
19 KOG4004|consensus 95.6 0.0049 1.1E-07 53.0 1.2 45 232-276 79-132 (259)
20 KOG4004|consensus 95.6 0.0055 1.2E-07 52.8 1.5 45 79-123 79-134 (259)
21 smart00057 FIMAC factor I memb 95.5 0.012 2.6E-07 42.4 2.6 45 231-276 23-69 (69)
22 smart00057 FIMAC factor I memb 94.6 0.027 5.9E-07 40.6 2.4 43 78-120 23-68 (69)
23 KOG3626|consensus 91.3 0.097 2.1E-06 53.9 1.5 45 233-277 519-581 (735)
24 TIGR00805 oat sodium-independe 90.8 0.12 2.5E-06 52.8 1.6 33 16-51 448-482 (633)
25 TIGR00805 oat sodium-independe 90.8 0.13 2.8E-06 52.4 1.9 27 79-105 453-480 (633)
26 KOG3626|consensus 86.6 0.35 7.6E-06 49.9 1.6 27 79-105 518-545 (735)
27 COG3350 Uncharacterized conser 31.3 26 0.00056 23.8 1.0 8 237-244 3-10 (53)
28 PRK13244 protease inhibitor pr 29.4 24 0.00052 29.2 0.7 28 231-258 100-138 (145)
29 KOG4597|consensus 28.6 54 0.0012 32.4 3.0 40 230-270 129-168 (560)
No 1
>cd01327 KAZAL_PSTI Kazal-type pancreatic secretory trypsin inhibitors (PSTI) and related proteins, including the second domain of the ovomucoid turkey inhibitor and the C-terminal domain of the esophagus cancer-related gene-2 protein (ECRG-2), are members of the superfamily of kazal-type proteinase inhibitors and follistatin-like proteins.
Probab=99.56 E-value=2.7e-15 Score=99.45 Aligned_cols=43 Identities=44% Similarity=0.892 Sum_probs=41.3
Q ss_pred CCCCCcCCCcccCCCceecccchhhhhhhcCCCceeEeeeccC
Q psy14246 232 RICPTIYDPICGTDNKTYSNDCFLQMENCRSRSLVQKLYHGQC 274 (286)
Q Consensus 232 ~~C~~~~~PVCGsDg~TY~N~C~l~~~~C~~~~~i~v~~~G~C 274 (286)
..||.+|+|||||||+||.|+|+|+.++|..+..|+++|.|+|
T Consensus 3 ~~Cp~~~~PVCGsDg~TY~N~C~l~~~~c~~~~~i~~~~~G~C 45 (45)
T cd01327 3 FGCPKDYDPVCGTDGVTYSNECLLCAENLKRQTNIRIKHDGEC 45 (45)
T ss_pred CCCCCCCCceeCCCCCEeCCHhHHHHHHhccCCCeEEeecCCC
Confidence 4799999999999999999999999999999999999999998
No 2
>smart00280 KAZAL Kazal type serine protease inhibitors. Kazal type serine protease inhibitors and follistatin-like domains.
Probab=99.55 E-value=3.6e-15 Score=99.46 Aligned_cols=45 Identities=42% Similarity=0.979 Sum_probs=43.2
Q ss_pred CCCCCCCcCCCcccCCCceecccchhhhhhhcCCCceeEeeeccC
Q psy14246 230 CARICPTIYDPICGTDNKTYSNDCFLQMENCRSRSLVQKLYHGQC 274 (286)
Q Consensus 230 C~~~C~~~~~PVCGsDg~TY~N~C~l~~~~C~~~~~i~v~~~G~C 274 (286)
|+..||.+++|||||||+||.|+|+|+.++|..+..|+|+|.|+|
T Consensus 2 C~~~C~~~~~pVCgsdg~TY~N~C~l~~~~c~~~~~i~~~~~G~C 46 (46)
T smart00280 2 CPEACPREYDPVCGSDGVTYSNECHLCKAACESGKSIEVKHDGPC 46 (46)
T ss_pred CCCCCCCCCCccCCCCCCEeCCHhHHHHHHhcCCCCeEEeecCCC
Confidence 677899999999999999999999999999999999999999987
No 3
>PF00050 Kazal_1: Kazal-type serine protease inhibitor domain; InterPro: IPR002350 Peptide proteinase inhibitors can be found as single domain proteins or as single or multiple domains within proteins; these are referred to as either simple or compound inhibitors, respectively. In many cases they are synthesised as part of a larger precursor protein, either as a prepropeptide or as an N-terminal domain associated with an inactive peptidase or zymogen. This domain prevents access of the substrate to the active site. Removal of the N-terminal inhibitor domain either by interaction with a second peptidase or by autocatalytic cleavage activates the zymogen. Other inhibitors interact direct with proteinases using a simple noncovalent lock and key mechanism; while yet others use a conformational change-based trapping mechanism that depends on their structural and thermodynamic properties. This family of Kazal inhibitors, belongs to MEROPS inhibitor family I1, clan IA. They inhibit serine peptidases of the S1 family (IPR001254 from INTERPRO) []. The members are primarily metazoan, but includes exceptions in the alveolata (apicomplexa), stramenopiles, higher plants and bacteria. Kazal inhibitors, which inhibit a number of serine proteases (such as trypsin and elastase), belong to family of proteins that includes pancreatic secretory trypsin inhibitor; avian ovomucoid; acrosin inhibitor; and elastase inhibitor. These proteins contain between 1 and 7 Kazal-type inhibitor repeats [, ]. The structure of the Kazal repeat includes a large quantity of extended chain, 2 short alpha-helices and a 3-stranded anti-parallel beta sheet [].The inhibitor makes 11 contacts with its enzyme substrate: unusually, 8 of these important residues are hypervariable []. Altering the enzyme-contact residues, and especially that of the active site bond, affects the the strength of inhibition and specificity of the inhibitor for particular serine proteases [, ]. The presence of this Pfam domain is usually indicative of serine protease inhibitors, however, Kazal-like domains are also seen in the extracellular part of agrins which are not known to be proteinase inhibitors.; GO: 0005515 protein binding; PDB: 1HPT_A 1CGI_I 1CGJ_I 2P6A_D 3HH2_C 2B0U_D 2BUS_A 1BUS_A 1OVO_A 3OVO_A ....
Probab=99.37 E-value=3.1e-13 Score=90.92 Aligned_cols=41 Identities=46% Similarity=0.909 Sum_probs=34.7
Q ss_pred CCCcCCCcccCCCceecccchhhhhhhcCCCceeEeeeccC
Q psy14246 234 CPTIYDPICGTDNKTYSNDCFLQMENCRSRSLVQKLYHGQC 274 (286)
Q Consensus 234 C~~~~~PVCGsDg~TY~N~C~l~~~~C~~~~~i~v~~~G~C 274 (286)
|+.+++|||||||+||.|+|+|..+.-+.+..|.|+|.|+|
T Consensus 8 C~~~~~PVCGsdg~TY~N~C~lC~~~~~~~~~i~~~~~G~C 48 (48)
T PF00050_consen 8 CPREYDPVCGSDGVTYSNECELCAANRRSGKNIRIAHDGPC 48 (48)
T ss_dssp EESSCS-EEETTSEEESSHHHHHHHHHHTTTSS-EEEESS-
T ss_pred CCCCCCceECCCCCCccccchhhhhhcccCCCeEEeecCCC
Confidence 88999999999999999999996555588889999999998
No 4
>smart00280 KAZAL Kazal type serine protease inhibitors. Kazal type serine protease inhibitors and follistatin-like domains.
Probab=99.34 E-value=6.1e-13 Score=88.62 Aligned_cols=43 Identities=40% Similarity=0.928 Sum_probs=39.6
Q ss_pred cccCCCCCCCceEcCCCceecccccchhhhccCC--ceeeccCCC
Q psy14246 77 CNHQCDDRREFVCGSDNKFYKSPCEMKRENCGVG--IELSHLGPC 119 (286)
Q Consensus 77 C~~~C~~~~~PVCGsdG~tY~n~C~l~~a~C~~~--i~~~~~G~C 119 (286)
|+..|+..+.||||+||+||.|+|+|+.++|..+ |.++|.|+|
T Consensus 2 C~~~C~~~~~pVCgsdg~TY~N~C~l~~~~c~~~~~i~~~~~G~C 46 (46)
T smart00280 2 CPEACPREYDPVCGSDGVTYSNECHLCKAACESGKSIEVKHDGPC 46 (46)
T ss_pred CCCCCCCCCCccCCCCCCEeCCHhHHHHHHhcCCCCeEEeecCCC
Confidence 6678999999999999999999999999999755 899999987
No 5
>PF07648 Kazal_2: Kazal-type serine protease inhibitor domain; InterPro: IPR011497 This domain is usually indicative of serine protease inhibitors that belong to Merops inhibitor families: I1, I2, I17 and I31. However, kazal-like domains are also seen in the extracellular part of agrins, which are not known to be protease inhibitors. Kazal domains often occur in tandem arrays and have a central alpha-helix, a short two-stranded antiparallel beta-sheet and several disulphide bonds [, , ]. The amino terminal segment of this domain binds to the active site of its target proteases, thus inhibiting their function.; PDB: 2KMP_A 1LDT_L 2KMR_A 2KMO_A 2KMQ_A 1AN1_I 4E0S_B 3T5O_A 4A5W_B 1LR7_A ....
Probab=99.33 E-value=5.2e-13 Score=86.93 Aligned_cols=41 Identities=51% Similarity=1.122 Sum_probs=38.5
Q ss_pred CCCcCC-CcccCCCceecccchhhhhhhcCCCceeEeeeccC
Q psy14246 234 CPTIYD-PICGTDNKTYSNDCFLQMENCRSRSLVQKLYHGQC 274 (286)
Q Consensus 234 C~~~~~-PVCGsDg~TY~N~C~l~~~~C~~~~~i~v~~~G~C 274 (286)
||.++. ||||+||+||.|+|+|+.++|..+..|+++|.|+|
T Consensus 1 C~~~~~~PVCg~dg~ty~n~C~l~~~~c~~~~~~~~~~~g~C 42 (42)
T PF07648_consen 1 CPREYSSPVCGSDGKTYSNECELRCANCRTNSKIQIVHDGSC 42 (42)
T ss_dssp EESSSSSTEEETTSEEESSHHHHHHHHHHHTTTCEEEEESSS
T ss_pred CcCCCCCCEEcCCCCEEhhHHHHHHHHHhcCCCeEEEeCCCC
Confidence 567777 99999999999999999999999999999999998
No 6
>cd01327 KAZAL_PSTI Kazal-type pancreatic secretory trypsin inhibitors (PSTI) and related proteins, including the second domain of the ovomucoid turkey inhibitor and the C-terminal domain of the esophagus cancer-related gene-2 protein (ECRG-2), are members of the superfamily of kazal-type proteinase inhibitors and follistatin-like proteins.
Probab=99.33 E-value=7.9e-13 Score=87.62 Aligned_cols=41 Identities=32% Similarity=0.621 Sum_probs=37.7
Q ss_pred cCCCCCCCceEcCCCceecccccchhhhccCC--ceeeccCCC
Q psy14246 79 HQCDDRREFVCGSDNKFYKSPCEMKRENCGVG--IELSHLGPC 119 (286)
Q Consensus 79 ~~C~~~~~PVCGsdG~tY~n~C~l~~a~C~~~--i~~~~~G~C 119 (286)
..||..+.|||||||+||.|+|+|..++|..+ |.++|.|+|
T Consensus 3 ~~Cp~~~~PVCGsDg~TY~N~C~l~~~~c~~~~~i~~~~~G~C 45 (45)
T cd01327 3 FGCPKDYDPVCGTDGVTYSNECLLCAENLKRQTNIRIKHDGEC 45 (45)
T ss_pred CCCCCCCCceeCCCCCEeCCHhHHHHHHhccCCCeEEeecCCC
Confidence 47899999999999999999999999988776 899999987
No 7
>cd00104 KAZAL_FS Kazal type serine protease inhibitors and follistatin-like domains. Kazal inhibitors inhibit serine proteases, such as, trypsin, chyomotrypsin, avian ovomucoids, and elastases. The inhibitory domain has one reactive site peptide bond, which serves the cognate enzyme as substrate. The reactive site peptide bond is a combining loop which has an identical conformation in all Kazal inhibitors and in all enzyme/inhibitor complexes. These Kazal domains (small hydrophobic core of alpha/beta structure with 3 to 4 disulfide bonds) often occur in tandem arrays. Similar domains are also present in follistatin (FS) and follistatin-like family members, which play an important role in tissue specific regulation. The FS domain consists of an N-terminal beta hairpin (FOLN/EGF-like domain) and a Kazal-like domain and has five disulfide bonds. Although the Kazal-like FS substructure is similar to Kazal proteinase inhibitors, no FS domain has yet been shown to be a proteinase inhibitor.
Probab=99.31 E-value=1.7e-12 Score=84.25 Aligned_cols=41 Identities=49% Similarity=1.072 Sum_probs=39.0
Q ss_pred CCCcCCCcccCCCceecccchhhhhhhcCCCceeEeeeccC
Q psy14246 234 CPTIYDPICGTDNKTYSNDCFLQMENCRSRSLVQKLYHGQC 274 (286)
Q Consensus 234 C~~~~~PVCGsDg~TY~N~C~l~~~~C~~~~~i~v~~~G~C 274 (286)
||.++.||||+||+||.|+|+|+.++|..+..|.+.|.|+|
T Consensus 1 C~~~~~pVCgsdg~tY~n~C~~~~~~c~~~~~~~~~~~g~C 41 (41)
T cd00104 1 CPKEYDPVCGSDGKTYSNECHLGCAACRSGRSITVAHNGPC 41 (41)
T ss_pred CCCCCCccCCCCCCEECCHhhhhHHhhcCCCCeEEEeccCC
Confidence 78889999999999999999999999998889999999987
No 8
>cd01328 FSL_SPARC Follistatin-like SPARC (secreted protein, acidic, and rich in cysteines) domain; SPARC/BM-40/osteonectin is a multifunctional glycoprotein which modulates cellular interaction with the extracellular matrix by its binding to structural matrix proteins such as collagen and vitronectin. The protein it composed of an N-terminal acidic region, a follistatin (FS) domain and an EF-hand calcium binding domain. The FS domain consists of an N-terminal beta hairpin (FOLN/EGF-like domain) and a small hydrophobic core of alpha/beta structure (Kazal domain) and has five disulfide bonds and a conserved N-glycosylation site. The FSL_SPARC domain is a member of the superfamily of kazal-like proteinase inhibitors and follistatin-like proteins.
Probab=99.10 E-value=6e-11 Score=88.94 Aligned_cols=49 Identities=29% Similarity=0.647 Sum_probs=42.0
Q ss_pred ccCCCCCCCcC---CCcccCCCceecccchhhhhhhcCC-----------CceeEeeeccCCC
Q psy14246 228 KGCARICPTIY---DPICGTDNKTYSNDCFLQMENCRSR-----------SLVQKLYHGQCGQ 276 (286)
Q Consensus 228 ~~C~~~C~~~~---~PVCGsDg~TY~N~C~l~~~~C~~~-----------~~i~v~~~G~C~~ 276 (286)
++|...||..+ +|||||||+||+|+|+|++++|..+ ..|+|.|.|+|.+
T Consensus 23 CvC~~~Cp~~~~~~~~VCGsDg~TY~s~C~L~r~~C~~~~~~~~~~~~~~~~l~i~Y~G~Ck~ 85 (86)
T cd01328 23 CVCIDPCPEEVDDRRKVCTNDNETFDSDCELYRTRCLCKGGKKGCRGPKYQHLHLDYYGECKE 85 (86)
T ss_pred EecCCcCCCCCCCCCceeCCCCCCcccHhHHhhhHhccCCCCcCCCCCccCeEEEEeeccccC
Confidence 45788899865 6699999999999999999999743 3699999999975
No 9
>PF07648 Kazal_2: Kazal-type serine protease inhibitor domain; InterPro: IPR011497 This domain is usually indicative of serine protease inhibitors that belong to Merops inhibitor families: I1, I2, I17 and I31. However, kazal-like domains are also seen in the extracellular part of agrins, which are not known to be protease inhibitors. Kazal domains often occur in tandem arrays and have a central alpha-helix, a short two-stranded antiparallel beta-sheet and several disulphide bonds [, , ]. The amino terminal segment of this domain binds to the active site of its target proteases, thus inhibiting their function.; PDB: 2KMP_A 1LDT_L 2KMR_A 2KMO_A 2KMQ_A 1AN1_I 4E0S_B 3T5O_A 4A5W_B 1LR7_A ....
Probab=99.08 E-value=3e-11 Score=78.56 Aligned_cols=39 Identities=41% Similarity=0.894 Sum_probs=34.8
Q ss_pred CCCCCC-ceEcCCCceecccccchhhhccCC--ceeeccCCC
Q psy14246 81 CDDRRE-FVCGSDNKFYKSPCEMKRENCGVG--IELSHLGPC 119 (286)
Q Consensus 81 C~~~~~-PVCGsdG~tY~n~C~l~~a~C~~~--i~~~~~G~C 119 (286)
|+..+. ||||+||+||.|+|+|++++|..+ +++.+.|+|
T Consensus 1 C~~~~~~PVCg~dg~ty~n~C~l~~~~c~~~~~~~~~~~g~C 42 (42)
T PF07648_consen 1 CPREYSSPVCGSDGKTYSNECELRCANCRTNSKIQIVHDGSC 42 (42)
T ss_dssp EESSSSSTEEETTSEEESSHHHHHHHHHHHTTTCEEEEESSS
T ss_pred CcCCCCCCEEcCCCCEEhhHHHHHHHHHhcCCCeEEEeCCCC
Confidence 566666 999999999999999999999865 899999987
No 10
>cd00104 KAZAL_FS Kazal type serine protease inhibitors and follistatin-like domains. Kazal inhibitors inhibit serine proteases, such as, trypsin, chyomotrypsin, avian ovomucoids, and elastases. The inhibitory domain has one reactive site peptide bond, which serves the cognate enzyme as substrate. The reactive site peptide bond is a combining loop which has an identical conformation in all Kazal inhibitors and in all enzyme/inhibitor complexes. These Kazal domains (small hydrophobic core of alpha/beta structure with 3 to 4 disulfide bonds) often occur in tandem arrays. Similar domains are also present in follistatin (FS) and follistatin-like family members, which play an important role in tissue specific regulation. The FS domain consists of an N-terminal beta hairpin (FOLN/EGF-like domain) and a Kazal-like domain and has five disulfide bonds. Although the Kazal-like FS substructure is similar to Kazal proteinase inhibitors, no FS domain has yet been shown to be a proteinase inhibitor.
Probab=99.07 E-value=7.8e-11 Score=76.35 Aligned_cols=39 Identities=41% Similarity=0.936 Sum_probs=35.2
Q ss_pred CCCCCCceEcCCCceecccccchhhhccCC--ceeeccCCC
Q psy14246 81 CDDRREFVCGSDNKFYKSPCEMKRENCGVG--IELSHLGPC 119 (286)
Q Consensus 81 C~~~~~PVCGsdG~tY~n~C~l~~a~C~~~--i~~~~~G~C 119 (286)
||..+.||||+||+||.|+|+|++++|..+ |.+.+.|+|
T Consensus 1 C~~~~~pVCgsdg~tY~n~C~~~~~~c~~~~~~~~~~~g~C 41 (41)
T cd00104 1 CPKEYDPVCGSDGKTYSNECHLGCAACRSGRSITVAHNGPC 41 (41)
T ss_pred CCCCCCccCCCCCCEECCHhhhhHHhhcCCCCeEEEeccCC
Confidence 677889999999999999999999999754 888999987
No 11
>PF00050 Kazal_1: Kazal-type serine protease inhibitor domain; InterPro: IPR002350 Peptide proteinase inhibitors can be found as single domain proteins or as single or multiple domains within proteins; these are referred to as either simple or compound inhibitors, respectively. In many cases they are synthesised as part of a larger precursor protein, either as a prepropeptide or as an N-terminal domain associated with an inactive peptidase or zymogen. This domain prevents access of the substrate to the active site. Removal of the N-terminal inhibitor domain either by interaction with a second peptidase or by autocatalytic cleavage activates the zymogen. Other inhibitors interact direct with proteinases using a simple noncovalent lock and key mechanism; while yet others use a conformational change-based trapping mechanism that depends on their structural and thermodynamic properties. This family of Kazal inhibitors, belongs to MEROPS inhibitor family I1, clan IA. They inhibit serine peptidases of the S1 family (IPR001254 from INTERPRO) []. The members are primarily metazoan, but includes exceptions in the alveolata (apicomplexa), stramenopiles, higher plants and bacteria. Kazal inhibitors, which inhibit a number of serine proteases (such as trypsin and elastase), belong to family of proteins that includes pancreatic secretory trypsin inhibitor; avian ovomucoid; acrosin inhibitor; and elastase inhibitor. These proteins contain between 1 and 7 Kazal-type inhibitor repeats [, ]. The structure of the Kazal repeat includes a large quantity of extended chain, 2 short alpha-helices and a 3-stranded anti-parallel beta sheet [].The inhibitor makes 11 contacts with its enzyme substrate: unusually, 8 of these important residues are hypervariable []. Altering the enzyme-contact residues, and especially that of the active site bond, affects the the strength of inhibition and specificity of the inhibitor for particular serine proteases [, ]. The presence of this Pfam domain is usually indicative of serine protease inhibitors, however, Kazal-like domains are also seen in the extracellular part of agrins which are not known to be proteinase inhibitors.; GO: 0005515 protein binding; PDB: 1HPT_A 1CGI_I 1CGJ_I 2P6A_D 3HH2_C 2B0U_D 2BUS_A 1BUS_A 1OVO_A 3OVO_A ....
Probab=99.03 E-value=8.3e-11 Score=79.04 Aligned_cols=39 Identities=41% Similarity=0.836 Sum_probs=29.4
Q ss_pred CCCCCCceEcCCCceecccccchhhhccCC--ceeeccCCC
Q psy14246 81 CDDRREFVCGSDNKFYKSPCEMKRENCGVG--IELSHLGPC 119 (286)
Q Consensus 81 C~~~~~PVCGsdG~tY~n~C~l~~a~C~~~--i~~~~~G~C 119 (286)
|+..+.||||+||+||.|+|+|-.+.-..+ |.++|.|+|
T Consensus 8 C~~~~~PVCGsdg~TY~N~C~lC~~~~~~~~~i~~~~~G~C 48 (48)
T PF00050_consen 8 CPREYDPVCGSDGVTYSNECELCAANRRSGKNIRIAHDGPC 48 (48)
T ss_dssp EESSCS-EEETTSEEESSHHHHHHHHHHTTTSS-EEEESS-
T ss_pred CCCCCCceECCCCCCccccchhhhhhcccCCCeEEeecCCC
Confidence 788999999999999999999932222333 999999997
No 12
>cd01328 FSL_SPARC Follistatin-like SPARC (secreted protein, acidic, and rich in cysteines) domain; SPARC/BM-40/osteonectin is a multifunctional glycoprotein which modulates cellular interaction with the extracellular matrix by its binding to structural matrix proteins such as collagen and vitronectin. The protein it composed of an N-terminal acidic region, a follistatin (FS) domain and an EF-hand calcium binding domain. The FS domain consists of an N-terminal beta hairpin (FOLN/EGF-like domain) and a small hydrophobic core of alpha/beta structure (Kazal domain) and has five disulfide bonds and a conserved N-glycosylation site. The FSL_SPARC domain is a member of the superfamily of kazal-like proteinase inhibitors and follistatin-like proteins.
Probab=98.92 E-value=6.1e-10 Score=83.51 Aligned_cols=47 Identities=23% Similarity=0.622 Sum_probs=39.0
Q ss_pred cccccccCCCCCCCCCCCCCC--CCCceEcCCCcccccHhHHHHHhcCCc
Q psy14246 4 CMSQERNKNGAIACPVSCEGE--KERIICGSDGNVYSSECEMRMLNCGSE 51 (286)
Q Consensus 4 ~~~~~~~~~~~~~C~~~C~~~--~~~PVCGsDG~tY~n~C~l~~a~C~~~ 51 (286)
|..++ ++++.|+|...||.+ ...|||||||+||+|+|+|++++|...
T Consensus 13 C~~d~-~~~p~CvC~~~Cp~~~~~~~~VCGsDg~TY~s~C~L~r~~C~~~ 61 (86)
T cd01328 13 CEVDD-ENTPKCVCIDPCPEEVDDRRKVCTNDNETFDSDCELYRTRCLCK 61 (86)
T ss_pred eeECC-CCCeEEecCCcCCCCCCCCCceeCCCCCCcccHhHHhhhHhccC
Confidence 44443 557899999999987 236799999999999999999999755
No 13
>KOG4578|consensus
Probab=98.35 E-value=1.7e-07 Score=85.42 Aligned_cols=79 Identities=24% Similarity=0.484 Sum_probs=58.5
Q ss_pred CCCCCCCCCCCCCCceEcCCCcccccHhHHHHHhcCCcCCccccCCCCCcccCCCCCCC-------C-CCccccCCCCCC
Q psy14246 14 AIACPVSCEGEKERIICGSDGNVYSSECEMRMLNCGSECDLKKSTCGEKVVPVPLHHCP-------T-TALCNHQCDDRR 85 (286)
Q Consensus 14 ~~~C~~~C~~~~~~PVCGsDG~tY~n~C~l~~a~C~~~~~~~~g~C~~~~~~~~~~~C~-------~-~~~C~~~C~~~~ 85 (286)
...|...|.+. ..|||||||+||.+.|+|++|+|.+.+. ...+.|.|. + ..+-... +..|
T Consensus 31 d~~c~l~C~~~-~kPvCasDGrty~srCe~qRAkC~dpql----------~~~yrG~Ck~C~~erk~a~eQa~k~-~~vF 98 (421)
T KOG4578|consen 31 DAACQLECDDN-EKPVCASDGRTYPSRCELQRAKCGDPQL----------SLKYRGSCKACLEERKFAREQAEKD-PGVF 98 (421)
T ss_pred chhhccccCCC-CCCccccCCccchhHHHHHHhhcCCCce----------eEEecCcHHHHHHHHHHHHHhhhcC-Ccee
Confidence 34577889998 7999999999999999999999998863 333444332 0 0011133 6688
Q ss_pred CceEcCCCceecccccchh
Q psy14246 86 EFVCGSDNKFYKSPCEMKR 104 (286)
Q Consensus 86 ~PVCGsdG~tY~n~C~l~~ 104 (286)
.|-|+.||..-+-.||-..
T Consensus 99 vPeC~~DG~f~qvQCh~yt 117 (421)
T KOG4578|consen 99 VPECRKDGNFAQVQCHGYT 117 (421)
T ss_pred cccccCCCCeeeEEecccc
Confidence 9999999998888887543
No 14
>KOG4578|consensus
Probab=98.23 E-value=3.1e-07 Score=83.67 Aligned_cols=79 Identities=34% Similarity=0.685 Sum_probs=58.3
Q ss_pred CccccCCCCCCCceEcCCCceecccccchhhhccCC-ceeeccCCCCCCCCC----CCCCCCCCCCCCCCCCeecCCCcE
Q psy14246 75 ALCNHQCDDRREFVCGSDNKFYKSPCEMKRENCGVG-IELSHLGPCNNISAH----RENCPVNCDQAPLDGPICGSDGNV 149 (286)
Q Consensus 75 ~~C~~~C~~~~~PVCGsdG~tY~n~C~l~~a~C~~~-i~~~~~G~C~~~~~~----~~~C~~~C~~~~~~~PVCGsDG~T 149 (286)
..|...|.....|||||||+||.+.|+|++|.|... +.|+|.|.|...-.. ++.-..+ + ..+.|-|+.||..
T Consensus 32 ~~c~l~C~~~~kPvCasDGrty~srCe~qRAkC~dpql~~~yrG~Ck~C~~erk~a~eQa~k~-~--~vFvPeC~~DG~f 108 (421)
T KOG4578|consen 32 AACQLECDDNEKPVCASDGRTYPSRCELQRAKCGDPQLSLKYRGSCKACLEERKFAREQAEKD-P--GVFVPECRKDGNF 108 (421)
T ss_pred hhhccccCCCCCCccccCCccchhHHHHHHhhcCCCceeEEecCcHHHHHHHHHHHHHhhhcC-C--ceecccccCCCCe
Confidence 346678888779999999999999999999999886 999999999732100 0111111 1 2689999999976
Q ss_pred Eecccce
Q psy14246 150 YKTNCQM 156 (286)
Q Consensus 150 Y~n~C~l 156 (286)
-.-.|+-
T Consensus 109 ~qvQCh~ 115 (421)
T KOG4578|consen 109 AQVQCHG 115 (421)
T ss_pred eeEEecc
Confidence 6655544
No 15
>cd01330 KAZAL_SLC21 The kazal-type serine protease inhibitor domain has been detected in an extracellular loop region of solute carrier 21 (SLC21) family members (organic anion transporters) , which may regulate the specificity of anion uptake. The KAZAL_SLC21 domain is a member of the superfamily of kazal-like proteinase inhibitors and follistatin-like proteins.
Probab=97.41 E-value=6.9e-05 Score=51.41 Aligned_cols=28 Identities=29% Similarity=0.726 Sum_probs=23.2
Q ss_pred CCCCCCCceEcCCCcccccHhHHHHHhcCCc
Q psy14246 21 CEGEKERIICGSDGNVYSSECEMRMLNCGSE 51 (286)
Q Consensus 21 C~~~~~~PVCGsDG~tY~n~C~l~~a~C~~~ 51 (286)
|+...+.||||+||+||.|.|++- |...
T Consensus 11 C~~~~~~PVCg~~g~tY~SpC~AG---C~~~ 38 (54)
T cd01330 11 CSESAYSPVCGENGITYFSPCHAG---CTNS 38 (54)
T ss_pred CCCCCcCCccCCCCCEEcCHhHcC---Cccc
Confidence 444358999999999999999998 7654
No 16
>cd01330 KAZAL_SLC21 The kazal-type serine protease inhibitor domain has been detected in an extracellular loop region of solute carrier 21 (SLC21) family members (organic anion transporters) , which may regulate the specificity of anion uptake. The KAZAL_SLC21 domain is a member of the superfamily of kazal-like proteinase inhibitors and follistatin-like proteins.
Probab=97.39 E-value=7.9e-05 Score=51.12 Aligned_cols=27 Identities=30% Similarity=0.614 Sum_probs=23.2
Q ss_pred cCCCC-CCCceEcCCCceecccccchhh
Q psy14246 79 HQCDD-RREFVCGSDNKFYKSPCEMKRE 105 (286)
Q Consensus 79 ~~C~~-~~~PVCGsdG~tY~n~C~l~~a 105 (286)
..|+. .+.||||+||+||.|.|++.+.
T Consensus 9 C~C~~~~~~PVCg~~g~tY~SpC~AGC~ 36 (54)
T cd01330 9 CSCSESAYSPVCGENGITYFSPCHAGCT 36 (54)
T ss_pred CCCCCCCcCCccCCCCCEEcCHhHcCCc
Confidence 35666 6889999999999999999864
No 17
>KOG3555|consensus
Probab=97.25 E-value=0.00015 Score=66.80 Aligned_cols=50 Identities=30% Similarity=0.694 Sum_probs=43.5
Q ss_pred CCCCC-cCCCcccCCCceecccchhhhhhhcCCCceeEeeeccCCCCCCCC
Q psy14246 232 RICPT-IYDPICGTDNKTYSNDCFLQMENCRSRSLVQKLYHGQCGQPTEEP 281 (286)
Q Consensus 232 ~~C~~-~~~PVCGsDg~TY~N~C~l~~~~C~~~~~i~v~~~G~C~~~~~~~ 281 (286)
++||. -..+||||||+||++.|.|...+|...+.|.|+-.|+|.-+++.+
T Consensus 140 KpCpvaq~a~vCGsDghtYss~ckLe~~aC~~sksiav~c~g~cpcps~~d 190 (434)
T KOG3555|consen 140 KPCPVAQPAFVCGSDGHTYSSRCKLEYHACHVSKSIAVICEGPCPCPSEAD 190 (434)
T ss_pred ccCCcccccceecCCCCeehhhhhHHHHhhhhhhhhhhhhCCCCCCCCCCC
Confidence 37875 467899999999999999999999999999999999998765443
No 18
>KOG3555|consensus
Probab=96.28 E-value=0.002 Score=59.68 Aligned_cols=43 Identities=37% Similarity=0.807 Sum_probs=36.0
Q ss_pred cCCCC-CCCceEcCCCceecccccchhhhccCC--ceeeccCCCCC
Q psy14246 79 HQCDD-RREFVCGSDNKFYKSPCEMKRENCGVG--IELSHLGPCNN 121 (286)
Q Consensus 79 ~~C~~-~~~PVCGsdG~tY~n~C~l~~a~C~~~--i~~~~~G~C~~ 121 (286)
.+||. .-.+|||+||.||.+.|.|.-.+|..+ |.++-.|+|.-
T Consensus 140 KpCpvaq~a~vCGsDghtYss~ckLe~~aC~~sksiav~c~g~cpc 185 (434)
T KOG3555|consen 140 KPCPVAQPAFVCGSDGHTYSSRCKLEYHACHVSKSIAVICEGPCPC 185 (434)
T ss_pred ccCCcccccceecCCCCeehhhhhHHHHhhhhhhhhhhhhCCCCCC
Confidence 47886 457999999999999999999999987 55666888763
No 19
>KOG4004|consensus
Probab=95.63 E-value=0.0049 Score=53.04 Aligned_cols=45 Identities=29% Similarity=0.727 Sum_probs=37.2
Q ss_pred CCCCC----cCCCcccCCCceecccchhhhhhhcCCCc-----eeEeeeccCCC
Q psy14246 232 RICPT----IYDPICGTDNKTYSNDCFLQMENCRSRSL-----VQKLYHGQCGQ 276 (286)
Q Consensus 232 ~~C~~----~~~PVCGsDg~TY~N~C~l~~~~C~~~~~-----i~v~~~G~C~~ 276 (286)
..||. .+.-|||.|++||.++|+|..++|..+.. |.+.|.|+|.-
T Consensus 79 ~kCP~~~~~p~~KVC~nnNqTf~S~C~~~~~~C~~~~~~k~~k~hl~y~G~Ck~ 132 (259)
T KOG4004|consen 79 YKCPRKQQRPVHKVCGNNNQTFNSWCEMHKHSCESRYFIKVHKLHLKYQGSCKY 132 (259)
T ss_pred CCCCcccCCchhhhhcCCCcchhHHHHHHHhhhhhhcccccceeehhccccccc
Confidence 36775 46679999999999999999999987654 45599999964
No 20
>KOG4004|consensus
Probab=95.62 E-value=0.0055 Score=52.76 Aligned_cols=45 Identities=31% Similarity=0.691 Sum_probs=37.1
Q ss_pred cCCCC----CCCceEcCCCceecccccchhhhccCC-------ceeeccCCCCCCC
Q psy14246 79 HQCDD----RREFVCGSDNKFYKSPCEMKRENCGVG-------IELSHLGPCNNIS 123 (286)
Q Consensus 79 ~~C~~----~~~PVCGsdG~tY~n~C~l~~a~C~~~-------i~~~~~G~C~~~~ 123 (286)
-.||. ++.-|||.|++||.|.|+|.+.+|... +.+.|.|+|..+.
T Consensus 79 ~kCP~~~~~p~~KVC~nnNqTf~S~C~~~~~~C~~~~~~k~~k~hl~y~G~Ck~i~ 134 (259)
T KOG4004|consen 79 YKCPRKQQRPVHKVCGNNNQTFNSWCEMHKHSCESRYFIKVHKLHLKYQGSCKYIP 134 (259)
T ss_pred CCCCcccCCchhhhhcCCCcchhHHHHHHHhhhhhhcccccceeehhcccccccCC
Confidence 36776 567899999999999999999999754 3458899998654
No 21
>smart00057 FIMAC factor I membrane attack complex.
Probab=95.45 E-value=0.012 Score=42.39 Aligned_cols=45 Identities=20% Similarity=0.361 Sum_probs=38.8
Q ss_pred CCCCCCcCCCcccCCCcee--cccchhhhhhhcCCCceeEeeeccCCC
Q psy14246 231 ARICPTIYDPICGTDNKTY--SNDCFLQMENCRSRSLVQKLYHGQCGQ 276 (286)
Q Consensus 231 ~~~C~~~~~PVCGsDg~TY--~N~C~l~~~~C~~~~~i~v~~~G~C~~ 276 (286)
|..|+.....||..|+.+| .|.|+|....|..+ .+.|.|.|+|.+
T Consensus 23 P~qC~~~~~~vCv~~~~~~~t~S~C~~~a~~C~g~-~~~~~~~g~C~~ 69 (69)
T smart00057 23 PYECPKAGTDVCVEDGRSEKTLTYCKQKSLECLNP-KYKFLHIGSCTA 69 (69)
T ss_pred HhHCCCCCCCeeEecCceeeeecHHHHHHHHhcCC-CcEEeccCCCCC
Confidence 4568885568999999899 99999999999964 689999999964
No 22
>smart00057 FIMAC factor I membrane attack complex.
Probab=94.59 E-value=0.027 Score=40.57 Aligned_cols=43 Identities=23% Similarity=0.454 Sum_probs=37.2
Q ss_pred ccCCCCCCCceEcCCCcee--cccccchhhhccCC-ceeeccCCCC
Q psy14246 78 NHQCDDRREFVCGSDNKFY--KSPCEMKRENCGVG-IELSHLGPCN 120 (286)
Q Consensus 78 ~~~C~~~~~PVCGsdG~tY--~n~C~l~~a~C~~~-i~~~~~G~C~ 120 (286)
|..|+.....||..|+..| .|.|+|..-+|+.. +.+.+.|+|.
T Consensus 23 P~qC~~~~~~vCv~~~~~~~t~S~C~~~a~~C~g~~~~~~~~g~C~ 68 (69)
T smart00057 23 PYECPKAGTDVCVEDGRSEKTLTYCKQKSLECLNPKYKFLHIGSCT 68 (69)
T ss_pred HhHCCCCCCCeeEecCceeeeecHHHHHHHHhcCCCcEEeccCCCC
Confidence 3568875568999999999 99999999999876 8999999986
No 23
>KOG3626|consensus
Probab=91.30 E-value=0.097 Score=53.85 Aligned_cols=45 Identities=24% Similarity=0.611 Sum_probs=33.3
Q ss_pred CCC-CcCCCcccCCCceecccchhhhhh---------------hcC--CCceeEeeeccCCCC
Q psy14246 233 ICP-TIYDPICGTDNKTYSNDCFLQMEN---------------CRS--RSLVQKLYHGQCGQP 277 (286)
Q Consensus 233 ~C~-~~~~PVCGsDg~TY~N~C~l~~~~---------------C~~--~~~i~v~~~G~C~~~ 277 (286)
.|+ ..|.||||.||.||-++||+-... |.. .....++..|.|+..
T Consensus 519 ~C~~~~~~PVCg~~G~tY~SpChAGC~~~~~~~~~~~~ytnCsCv~~~~~~~~~a~~G~C~~~ 581 (735)
T KOG3626|consen 519 SCDTSEYEPVCGENGITYFSPCHAGCTESSGTSDGNTIYTNCSCVPTNKNGNGSAKKGYCPND 581 (735)
T ss_pred CCCCcCcCcccCCCCCEEeChhhhCCcccccCCCCceeeccccccccccCCCceeecCCCCCC
Confidence 455 679999999999999999975542 222 114567888888877
No 24
>TIGR00805 oat sodium-independent organic anion transporter. Proteins of the OAT family catalyze the Na+-independent facilitated transport of organic anions such as bromosulfobromophthalein and prostaglandins as well as conjugated and unconjugated bile acids (taurocholate and cholate, respectively). These transporters have been characterized in mammals, but homologues are present in C. elegans and A. thaliana. Some of the mammalian proteins exhibit a high degree of tissue specificity. For example, the rat OAT is found at high levels in liver and kidney and at lower levels in other tissues. These proteins possess 10-12 putative a-helical transmembrane spanners. They may catalyze electrogenic anion uniport or anion exchange.
Probab=90.81 E-value=0.12 Score=52.76 Aligned_cols=33 Identities=27% Similarity=0.698 Sum_probs=25.9
Q ss_pred CCCCC--CCCCCCCceEcCCCcccccHhHHHHHhcCCc
Q psy14246 16 ACPVS--CEGEKERIICGSDGNVYSSECEMRMLNCGSE 51 (286)
Q Consensus 16 ~C~~~--C~~~~~~PVCGsDG~tY~n~C~l~~a~C~~~ 51 (286)
.|..+ |+...+.||||.||.||-|.|++- |...
T Consensus 448 ~Cn~~C~C~~~~~~PVCg~~~~tY~SpC~AG---C~~~ 482 (633)
T TIGR00805 448 DCNRQCSCDSSFFDPVCGDNGLAYLSPCHAG---CSMS 482 (633)
T ss_pred ccCCCCCCCCCCcccccCCCCCEEECccccC---CCCc
Confidence 45544 554469999999999999999988 8643
No 25
>TIGR00805 oat sodium-independent organic anion transporter. Proteins of the OAT family catalyze the Na+-independent facilitated transport of organic anions such as bromosulfobromophthalein and prostaglandins as well as conjugated and unconjugated bile acids (taurocholate and cholate, respectively). These transporters have been characterized in mammals, but homologues are present in C. elegans and A. thaliana. Some of the mammalian proteins exhibit a high degree of tissue specificity. For example, the rat OAT is found at high levels in liver and kidney and at lower levels in other tissues. These proteins possess 10-12 putative a-helical transmembrane spanners. They may catalyze electrogenic anion uniport or anion exchange.
Probab=90.80 E-value=0.13 Score=52.40 Aligned_cols=27 Identities=33% Similarity=0.641 Sum_probs=23.0
Q ss_pred cCCCC-CCCceEcCCCceecccccchhh
Q psy14246 79 HQCDD-RREFVCGSDNKFYKSPCEMKRE 105 (286)
Q Consensus 79 ~~C~~-~~~PVCGsdG~tY~n~C~l~~a 105 (286)
+.|+. .|.||||.||.||-|.||.-+.
T Consensus 453 C~C~~~~~~PVCg~~~~tY~SpC~AGC~ 480 (633)
T TIGR00805 453 CSCDSSFFDPVCGDNGLAYLSPCHAGCS 480 (633)
T ss_pred CCCCCCCcccccCCCCCEEECccccCCC
Confidence 45654 7999999999999999998763
No 26
>KOG3626|consensus
Probab=86.58 E-value=0.35 Score=49.88 Aligned_cols=27 Identities=37% Similarity=0.693 Sum_probs=23.0
Q ss_pred cCCC-CCCCceEcCCCceecccccchhh
Q psy14246 79 HQCD-DRREFVCGSDNKFYKSPCEMKRE 105 (286)
Q Consensus 79 ~~C~-~~~~PVCGsdG~tY~n~C~l~~a 105 (286)
+.|+ ..+.||||.||.||-|.||.-++
T Consensus 518 C~C~~~~~~PVCg~~G~tY~SpChAGC~ 545 (735)
T KOG3626|consen 518 CSCDTSEYEPVCGENGITYFSPCHAGCT 545 (735)
T ss_pred CCCCCcCcCcccCCCCCEEeChhhhCCc
Confidence 4566 48999999999999999998764
No 27
>COG3350 Uncharacterized conserved protein [Function unknown]
Probab=31.35 E-value=26 Score=23.80 Aligned_cols=8 Identities=50% Similarity=1.468 Sum_probs=6.1
Q ss_pred cCCCcccC
Q psy14246 237 IYDPICGT 244 (286)
Q Consensus 237 ~~~PVCGs 244 (286)
..+||||+
T Consensus 3 ~iDPVcgm 10 (53)
T COG3350 3 VIDPVCGM 10 (53)
T ss_pred cccCCcCc
Confidence 35899986
No 28
>PRK13244 protease inhibitor protein; Provisional
Probab=29.40 E-value=24 Score=29.15 Aligned_cols=28 Identities=29% Similarity=0.743 Sum_probs=22.2
Q ss_pred CCCCCCcCCCcccC-----CC------ceecccchhhhh
Q psy14246 231 ARICPTIYDPICGT-----DN------KTYSNDCFLQME 258 (286)
Q Consensus 231 ~~~C~~~~~PVCGs-----Dg------~TY~N~C~l~~~ 258 (286)
...|+++|+||=.+ +| +||.|.|.|...
T Consensus 100 ~~~CT~~y~Pvtata~G~W~Gr~V~~~~tf~N~C~~~~~ 138 (145)
T PRK13244 100 EAMCTRDYDPVVVTATGVWQGKRVAYERTFANECVKKSQ 138 (145)
T ss_pred CCccccccCCEEEEEEEEECCEEEEEEEEecCceeEecc
Confidence 35899999998765 34 799999998864
No 29
>KOG4597|consensus
Probab=28.60 E-value=54 Score=32.37 Aligned_cols=40 Identities=25% Similarity=0.531 Sum_probs=32.0
Q ss_pred CCCCCCCcCCCcccCCCceecccchhhhhhhcCCCceeEee
Q psy14246 230 CARICPTIYDPICGTDNKTYSNDCFLQMENCRSRSLVQKLY 270 (286)
Q Consensus 230 C~~~C~~~~~PVCGsDg~TY~N~C~l~~~~C~~~~~i~v~~ 270 (286)
|.+.|-++-.--|.+||.||.| |.|...+|-.+..+.|.+
T Consensus 129 ~~~~~~~eP~~~~~d~~~k~~n-~t~cs~aCgKG~q~~iv~ 168 (560)
T KOG4597|consen 129 CIDRCEKEPSFTCADDGLKYYN-CTMCSEACGKGVQLRIVY 168 (560)
T ss_pred cccccccCCchhhhhcCceecc-eEehhhhhcCCceeeeEE
Confidence 4556667777789999999999 999999998876665543
Done!